Form 8-K - Current report:
SEC Accession No. 0001193125-24-253145
Filing Date
2024-11-07
Accepted
2024-11-07 16:16:01
Documents
15
Period of Report
2024-11-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d862589d8k.htm   iXBRL 8-K 25637
2 EX-99.1 d862589dex991.htm EX-99.1 48794
6 GRAPHIC g862589g1105044751791.jpg GRAPHIC 3298
  Complete submission text file 0001193125-24-253145.txt   210277

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rgls-20241107.xsd EX-101.SCH 2857
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rgls-20241107_lab.xml EX-101.LAB 17995
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rgls-20241107_pre.xml EX-101.PRE 11266
17 EXTRACTED XBRL INSTANCE DOCUMENT d862589d8k_htm.xml XML 3645
Mailing Address 4224 CAMPUS POINT COURT SUITE 210 SAN DIEGO CA 92121
Business Address 4224 CAMPUS POINT COURT SUITE 210 SAN DIEGO CA 92121 858-202-6300
Regulus Therapeutics Inc. (Filer) CIK: 0001505512 (see all company filings)

EIN.: 264738379 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35670 | Film No.: 241435994
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)